Skip to main content
Clinical Trials/NCT07639931
NCT07639931Not yet recruitingNot Applicable

Integration and Application Demonstration of Key Diagnosis and Treatment Technologies for Severe Acute High Altitude Disease

Tibet Autonomous Region People's Hospital1 site in 1 country3,035 target enrollmentStarted: July 1, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
3,035
Locations
1

Study Overview

Brief Summary

This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Meeting the diagnostic criteria for severe acute mountain sickness (including high-altitude pulmonary edema [HAPE] and high-altitude cerebral edema [HACE]).
  • Aged 18 to 75 years.
  • Rapid ascent to an altitude above 2500 m within 72 hours prior to onset.

Exclusion Criteria

  • History of severe cardiopulmonary diseases.
  • Pregnant women, patients with psychiatric disorders, inability to cooperate with treatment or follow-up, and patients with an expected survival of less than 6 months.
  • Patients with malignant tumors, severe hepatic or renal insufficiency, or immune system diseases requiring immunosuppressive therapy.

Investigators

Sponsor
Tibet Autonomous Region People's Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Gesang Lobb

First-Class Chief Physician, Department of Cardiovascular Medicine

Tibet Autonomous Region People's Hospital

Study Sites (1)

Loading locations...

Similar Trials